

536 50 1 Express Mail No: EE 006 333 182 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

98750-62

Application of: Dasseux, et al.

Confirmation No: 5585

Serial No.: 10/099,836

Group Art Unit: 1614

Filed: March 15, 2002

Examiner: To be assigned

For:

APOLIPOPROTEIN A-I

Attorney Docket No.: 9196-0022-999

TREAT DYSLIPIDEMIC

AGONISTS AND THEIR USE TO

DISORDERS

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents Arlington, VA 22202

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 19, 2002, in connection with above-identified application, Applicants submit herewith, a substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c) and (e) and a return copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. The content of the paper and computer readable copies of the Sequence Listing submitted herewith are the same. Moreover, as the Sequence Listing merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, the Sequence Listing does not introduce new matter into the application. Accordingly, Applicants respectfully request the entry of the paper and computer readable forms of the Sequence Listing into the application.

No fees are believed due in connection with this submission. However, if there is a fee due, please charge the required fee to the Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is attached.

Respectfully submitted,

Date: August 28, 2002

43,341

orgit Milladerure A. Corner,

(Reg. No.) 30,742

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711

(212) 790-9090



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/099,836

03/15/2002

Jean-Louis Dasseux

9196-0022-999

24341 Pennie & Edmonds, LLP 3300 Hillview Avenue Palo Alto, CA 94304



CONFIRMATION NO. 5585 FORMALITIES LETTER

OC00000008415423

Date Mailed: 08/19/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center Initial Patent Examination

ation bivision (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE